

Yao-Jun Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1608522/publications.pdf>

Version: 2024-02-01

137
papers

5,184
citations

87723

38
h-index

102304

66
g-index

146
all docs

146
docs citations

146
times ranked

5792
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 150-160.	0.8	137
2	Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Journal of Gastroenterology</i> , 2022, 57, 185-198.	2.3	16
3	Drug-coated balloon combined with provisional drug-eluting stent implantation for the treatment of de novo Medina 0,1,0 or 0,0,1 left main coronary bifurcation lesions: A proof-of-concept study. , 2022, 26, 218-225.		2
4	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110027.	1.4	91
5	Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria. <i>BMC Cancer</i> , 2021, 21, 147.	1.1	1
6	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3207-3216.	2.0	21
7	Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression. <i>Hepatology</i> , 2021, 73, 1717-1735.	3.6	147
8	Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 619461.	1.3	14
9	Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 657-670.	1.8	12
10	Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. <i>BMC Cancer</i> , 2021, 21, 775.	1.1	28
11	Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. <i>European Journal of Cancer</i> , 2021, 155, 85-96.	1.3	19
12	Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials. <i>Frontiers in Bioscience</i> , 2021, 26, 873.	0.8	6
13	Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , 2021, 398, 2149-2159.	6.3	175
14	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3Åyears results from the NANO multicenter Registry. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 537.	0.7	1
15	Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. <i>Immunotherapy</i> , 2021, , .	1.0	0
16	Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score. <i>Frontiers in Pharmacology</i> , 2021, 12, 819985.	1.6	9
17	Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 548-559.	0.5	23
18	Optical coherence tomography enables more accurate detection of functionally significant intermediate non-left main coronary artery stenoses than intravascular ultrasound: A meta-analysis of 6919 patients and 7537 lesions. <i>International Journal of Cardiology</i> , 2020, 301, 226-234.	0.8	19

#	ARTICLE	IF	CITATIONS
19	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
20	Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1639.	1.3	22
21	Feasibility of using deep learning to detect coronary artery disease based on facial photo. <i>European Heart Journal</i> , 2020, 41, 4400-4411.	1.0	67
22	<p>Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 337-345.	1.8	6
23	Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study. <i>International Journal of Surgery</i> , 2020, 77, 15-21.	1.1	3
24	Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. <i>Cancer Communications</i> , 2020, 40, 355-369.	3.7	16
25	Oneâ€year clinical results of the NANO registry: A multicenter, prospective allâ€comers registry study in patients receiving implantation of a polymerâ€free sirolimusâ€eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 658-664.	0.7	8
26	Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trial. <i>Surgery</i> , 2020, 167, 933-941.	1.0	10
27	<p>Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 377-384.	1.8	5
28	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study. <i>Cancers</i> , 2019, 11, 1116.	1.7	17
29	Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. <i>Oncolmmunology</i> , 2019, 8, e1652540.	2.1	55
30	A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy. <i>Cancer Communications</i> , 2019, 39, 1-11.	3.7	33
31	Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	15
32	Predictive factors for the benefit of tripleâ€drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 4200-4213.	1.3	9
33	12-Month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding 3.0Âmm. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 579-586.	0.7	13
34	Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 824-839.	3.6	62
35	Robot-assisted laparoscopic partial hepatic caudate lobectomy. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2019, 28, 292-297.	0.6	7
36	The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up?. <i>Medical Science Monitor</i> , 2019, 25, 4941-4951.	0.5	5

#	ARTICLE	IF	CITATIONS
37	Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2018, 8, e017231.	0.8	14
38	One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the <i>N₁eoV</i> as bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 617-622.	0.7	6
39	Intravascular imaging in cardiovascular ageing. <i>Experimental Gerontology</i> , 2018, 109, 31-37.	1.2	3
40	Use of sodium nitroprusside in retrograde percutaneous coronary intervention for chronic total occlusion. <i>Medicine (United States)</i> , 2018, 97, e11498.	0.4	2
41	Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. <i>Journal of Cancer</i> , 2018, 9, 1745-1753.	1.2	14
42	Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. <i>Cancers</i> , 2018, 10, 378.	1.7	36
43	Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions. <i>International Journal of Cardiology</i> , 2018, 272, 7-12.	0.8	16
44	Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1068-1077.e2.	0.2	19
45	Neointima and neoatherosclerotic characteristics in bare metal and first- and second-generation drug-eluting stents in patients admitted with cardiovascular events attributed to stent failure: an optical coherence tomography study. <i>EuroIntervention</i> , 2018, 13, e1831-e1840.	1.4	13
46	Invasive or non-invasive imaging for detecting high-risk coronary lesions?. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 165-179.	0.6	15
47	Optical coherence tomography assessment of a complex bifurcation lesion treated with double kissing Crush technique. <i>Medicine (United States)</i> , 2017, 96, e5740.	0.4	1
48	A head to head comparison of XINSORB bioresorbable sirolimus-eluting scaffold versus metallic sirolimus-eluting stent: 180 days follow-up in a porcine model. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1473-1481.	0.7	9
49	Left jackknife position: a novel position for laparoscopic hepatectomy. <i>Chinese Journal of Cancer</i> , 2017, 36, 31.	4.9	6
50	Assessing Hepatic Fibrosis Using 2-D Shear Wave Elastography in Patients with Liver Tumors: A Prospective Single-Center Study. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2522-2529.	0.7	13
51	Intravascular Ultrasound Classification of Plaque in Angiographic True Bifurcation Lesions of the Left Main Coronary Artery. <i>Chinese Medical Journal</i> , 2016, 129, 1538-1543.	0.9	5
52	Comparison between two-dimensional and three-dimensional quantitative coronary angiography for the prediction of functional severity in true bifurcation lesions: Insights from the randomized DK-CRUSH II, III, and IV trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 589-598.	0.7	5
53	Intravascular ultrasound-guided drug-eluting stent implantation: An updated meta-analysis of randomized control trials and observational studies. <i>International Journal of Cardiology</i> , 2016, 216, 133-139.	0.8	73
54	Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. <i>Oncology Letters</i> , 2016, 11, 2987-2994.	0.8	30

#	ARTICLE	IF	CITATIONS
55	Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2016, 35, 25.	4.9	37
56	Vulnerable plaque detection: an unrealistic quest or a feasible objective with a clinical value?. <i>Heart</i> , 2016, 102, 581-589.	1.2	27
57	Expression of Pim-3 in colorectal cancer and its relationship with prognosis. <i>Tumor Biology</i> , 2016, 37, 9151-9156.	0.8	14
58	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. <i>Oncolmmunology</i> , 2016, 5, e1083671.	2.1	56
59	Noninvasive Prediction of Atherosclerotic Progression: The PROSPECT-MSCT Study. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1009-1011.	2.3	27
60	The impact of dual antiplatelet therapy duration on primary composite endpoint after drug-eluting stent implantation: A meta-analysis of 10 randomized trials. <i>International Journal of Cardiology</i> , 2016, 202, 504-506.	0.8	1
61	Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. <i>Oncotarget</i> , 2016, 7, 27938-27945.	0.8	4
62	Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial. <i>EuroIntervention</i> , 2016, 12, 1279-1287.	1.4	16
63	Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. <i>EuroIntervention</i> , 2016, 12, e574-e583.	1.4	15
64	Clinical outcomes of "complete, partially complete, and incomplete" revascularisation at five-year follow-up after percutaneous intervention of unprotected left main coronary artery disease with drug-eluting stents. <i>EuroIntervention</i> , 2016, 12, e957-e963.	1.4	3
65	Comparison of intravascular ultrasound guided versus angiography guided drug eluting stent implantation: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 153.	0.7	81
66	Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 952-958.	0.7	9
67	Periprocedural myocardial infarction is associated with increased mortality in patients with coronary artery bifurcation lesions after implantation of a drug-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 696-705.	0.7	14
68	TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 24163-24177.	0.8	54
69	Clinical Impact of Dual Antiplatelet Therapy Use in Patients Following Everolimus-eluting Stent Implantation. <i>Chinese Medical Journal</i> , 2015, 128, 714-720.	0.9	3
70	Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. <i>Chinese Journal of Cancer</i> , 2015, 34, 205-16.	4.9	17
71	Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. <i>Heart</i> , 2015, 101, 271-278.	1.2	15
72	Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 63, 122-130.	1.8	101

#	ARTICLE	IF	CITATIONS
73	Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting. <i>Circulation</i> , 2015, 131, 1269-1277.	1.6	167
74	Smoking Is Associated With Adverse Clinical Outcomes in Patients Undergoing Revascularization With PCI or CABG. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1107-1115.	1.2	99
75	Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1489-1496.	0.7	7
76	Long-term therapy with sorafenib is associated with pancreatic atrophy. <i>Journal of Surgical Research</i> , 2015, 199, 314-321.	0.8	10
77	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: An analysis of the SYNTAX Study. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 199-206.	0.7	32
78	Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. <i>EuroIntervention</i> , 2015, 10, 1288-1298.	1.4	34
79	Angiographic and clinical comparisons of intravascular ultrasound- versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. <i>EuroIntervention</i> , 2015, 10, 1409-1417.	1.4	139
80	Biodegradable or biocompatible polymer drug-eluting stent: a Gordian knot. <i>EuroIntervention</i> , 2015, 11, 250-252.	1.4	2
81	Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial. <i>EuroIntervention</i> , 2015, 10, 1299-1306.	1.4	20
82	Left atrial appendage closure monitoring without sedation: a pilot study using intracardiac echocardiography through the oesophageal route. <i>EuroIntervention</i> , 2015, 11, 936-941.	1.4	29
83	Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. <i>EuroIntervention</i> , 2015, 11, 746-756.	1.4	42
84	Comparison of one-year clinical outcomes between intravascular ultrasound-guided versus angiography-guided implantation of drug-eluting stents for left main lesions: a single-center analysis of a 1,016-patient cohort. <i>Patient Preference and Adherence</i> , 2014, 8, 1299.	0.8	43
85	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. <i>Heart</i> , 2014, 100, 1158-1164.	1.2	216
86	Mesenchymal stem cells with overexpression of midkine enhance cell survival and attenuate cardiac dysfunction in a rat model of myocardial infarction. <i>Stem Cell Research and Therapy</i> , 2014, 5, 37.	2.4	35
87	Response to Letter Regarding Article, "Quantification of Incomplete Revascularization and Its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the Residual SYNTAX Score". <i>Circulation</i> , 2014, 129, e355-6.	1.6	1
88	Scaffold and Edge Vascular Response Following Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1361-1369.	1.1	23
89	Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: Role of autophagy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 995-1002.	0.9	59
90	The impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: A meta-analysis of 16 randomized trials. <i>Journal of Cardiology</i> , 2014, 64, 185-193.	0.8	15

#	ARTICLE	IF	CITATIONS
91	Short- and Long-Term Implications of a Bioresorbable Vascular Scaffold Implantation on the Local Endothelial Shear Stress Patterns. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 100-101.	1.1	11
92	Fusion of optical coherence tomographic and angiographic data for more accurate evaluation of the endothelial shear stress patterns and neointimal distribution after bioresorbable scaffold implantation: comparison with intravascular ultrasound-derived reconstructions. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 485-494.	0.7	37
93	Implications of a bioresorbable vascular scaffold implantation on vessel wall strain of the treated and the adjacent segments. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 477-484.	0.7	3
94	Effect of the Endothelial Shear Stress Patterns on Neointimal Proliferation Following Drug-Eluting Bioresorbable Vascular Scaffold Implantation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 315-324.	1.1	108
95	Assessing Bioresorbable Coronary Devices. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1130-1148.	2.3	60
96	Impact of the Complexity of Bifurcation Lesions Treated With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1266-1276.	1.1	153
97	Prognostic Value of Site SYNTAX Score and Rationale for Combining Anatomic and Clinical Factors in Decision Making. <i>Journal of the American College of Cardiology</i> , 2014, 64, 423-432.	1.2	48
98	NOBORI, ¢ biodegradable-polymer biolimus-eluting stent versus durable-polymer drug-eluting stents: A meta-analysis. <i>International Journal of Cardiology</i> , 2014, 174, 151-153.	0.8	2
99	Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. <i>European Journal of Pharmacology</i> , 2014, 728, 67-76.	1.7	128
100	Predicting 3-Year Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 464-470.	1.1	50
101	Temporal Evolution of Strut Light Intensity After Implantation of Bioresorbable Polymeric Intracoronary Scaffolds in the ABSORB Cohort B Trial. <i>Circulation Journal</i> , 2014, 78, 1873-1881.	0.7	12
102	Predictive Performance of SYNTAX Score II in Patients With Left Main and Multivessel Coronary Artery Disease. <i>Circulation Journal</i> , 2014, 78, 1942-1949.	0.7	64
103	68â€...Predicting 3-Year Mortality After PCI: Revised Clinical Syntax Model Based on Patient Level Data from 7 Contemporary Stent Trials. <i>Heart</i> , 2014, 100, A38.2-A39.	1.2	0
104	Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. <i>EuroIntervention</i> , 2014, 10, 672-680.	1.4	30
105	Stenting strategy for coronary artery bifurcation with drug-eluting stents: a meta-analysis of nine randomised trials and systematic review. <i>EuroIntervention</i> , 2014, 10, 561-569.	1.4	66
106	Bioresorbable scaffolds for coronary artery disease: current status and future prospective. <i>Chinese Medical Journal</i> , 2014, 127, 1141-8.	0.9	1
107	Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial. <i>Chinese Medical Journal</i> , 2014, 127, 2153-8.	0.9	14
108	Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 15 randomized trials. <i>Chinese Medical Journal</i> , 2014, 127, 2159-66.	0.9	5

#	ARTICLE	IF	CITATIONS
109	Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study. <i>Cardiovascular Ultrasound</i> , 2013, 11, 25.	0.5	7
110	Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 483-496.	0.4	34
111	Short-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2360-2369.	1.2	62
112	The Anatomic- and Clinical-Based NERS (New Risk Stratification) Score II to Predict Clinical Outcomes After Stenting Unprotected Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1233-1241.	1.1	24
113	Intracoronary Optical Coherence Tomography and Histology of Overlapping Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 523-532.	1.1	84
114	Radial approach for patients with ST-segment elevation acute coronary syndrome: It is definitely the best access site. <i>International Journal of Cardiology</i> , 2013, 168, 3140-3142.	0.8	0
115	TCT-837 Everolimus-eluting versus other rapamycin derivatives-eluting stents in patients with coronary artery disease: a meta-analysis of 16 randomized trials. <i>Journal of the American College of Cardiology</i> , 2013, 62, B253.	1.2	1
116	Comparison of Intravascular Ultrasound Versus Angiography Guided Drug-eluting Stent Implantation: A Meta-analysis of Randomized Trials and Observational Studies Involving 28,745 Patients. <i>American Journal of Cardiology</i> , 2013, 111, 41B.	0.7	0
117	The Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions. <i>Journal of the American College of Cardiology</i> , 2013, 61, 282-294.	1.2	257
118	Bioresorbable scaffolds: Current knowledge, potentialities and limitations experienced during their first clinical applications. <i>International Journal of Cardiology</i> , 2013, 167, 11-21.	0.8	56
119	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. <i>Heart</i> , 2013, 99, 1267-1274.	1.2	36
120	Bioresorbable vascular scaffolds in the clinical setting. <i>Interventional Cardiology</i> , 2013, 5, 639-646.	0.0	7
121	Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease. <i>International Journal of Molecular Sciences</i> , 2013, 14, 24492-24500.	1.8	109
122	The Ginsenoside Rg1 Prevents Transverse Aortic Constrictionâ€“Induced Left Ventricular Hypertrophy and Cardiac Dysfunction by Inhibiting Fibrosis and Enhancing Angiogenesis. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 50-57.	0.8	60
123	Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score. <i>Circulation</i> , 2013, 128, 141-151.	1.6	326
124	Intimal Flaps Detected by Optical Frequency Domain Imaging in the Proximal Segments of Native Coronary Arteries. <i>Circulation Journal</i> , 2013, 77, 2327-2333.	0.7	10
125	Bioresorbable scaffolds in the treatment of coronary artery disease. <i>Medical Devices: Evidence and Research</i> , 2013, 6, 37.	0.4	17
126	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. <i>EuroIntervention</i> , 2013, 9, 75-83.	1.4	60

#	ARTICLE	IF	CITATIONS
127	Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. <i>EuroIntervention</i> , 2013, 9, 269-276.	1.4	80
128	In vivo assessment of the three-dimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: fusion of frequency domain optical coherence tomography and angiography. <i>EuroIntervention</i> , 2013, 9, 890-890.	1.4	17
129	Revisiting: "Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients". <i>EuroIntervention</i> , 2013, 9, 891-892.	1.4	7
130	Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment. <i>EuroIntervention</i> , 2013, 9, R149-R154.	1.4	1
131	Acute Effects of Nicardipine and Esmolol on The Cardiac Cycle, Intracardiac Hemodynamic and Endothelial Shear Stress in Patients With Unstable Angina Pectoris and Moderate Coronary Stenosis: Results From Single Center, Randomized Study. <i>Cardiovascular Therapeutics</i> , 2012, 30, 162-171.	1.1	4
132	TCT-78 Long-Term (4-Year) Clinical Outcomes of Total Occlusions and Completeness of Revascularisation in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery Trial. <i>Journal of the American College of Cardiology</i> , 2012, 60, B25.	1.2	0
133	TCT-246 Comparison of intravascular ultrasound versus angiography guided drug-eluting stent implantation: a meta-analysis of randomized trials and observational studies involving 17,570 patients. <i>Journal of the American College of Cardiology</i> , 2012, 60, B70.	1.2	0
134	Bioresorbable Scaffolds: Current Evidence and Ongoing Clinical Trials. <i>Current Cardiology Reports</i> , 2012, 14, 626-634.	1.3	33
135	Angioscopy study from a large patient population comparing sirolimus-eluting stent with biodegradable versus durable polymer. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 420-428.	0.7	10
136	Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique. <i>EuroIntervention</i> , 2012, 8, 803-814.	1.4	40
137	Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. <i>EuroIntervention</i> , 2012, 8, 855-865.	1.4	163